(42) have demonstrated that effective cancer immunotherapies, while inducing immune activation in the tumor in the initial phase, only peripheral immune cells with sustained proliferation and activation are required for tumor rejection and eradication, with a key role played by a subset of CD4+ T cells. The gene discussed is CD4; the disease is neoplasm.